PRODUCT INFORMATION



TAPI-2

Item No. 14695

CAS Registry No.:	187034-31-7			
Formal Name:	N-[2-[2-(hydroxyamino)-			
	2-oxoethyl]-4-methyl-1-			
	oxopentyl]-3-methyl-L-valyl-N-(2-	\downarrow		
	aminoethyl)-L-alaninamide		н	Н
Synonym:	TNF Protease Inhibitor 2	0		Ï
MF:	$C_{19}H_{37}N_5O_5$	HO		
FW:	415.5	N Ý Ŭ	Y N	MH ₂
Purity:	≥95%	H O	, н	0
,				
Supplied as:	A crystalline solid			
Storage:	-20°C			
Stability:	≥4 years			
Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.				

Laboratory Procedures

TAPI-2 is supplied as a crystalline solid. A stock solution may be made by dissolving the TAPI-2 in the solvent of choice, which should be purged with an inert gas. TAPI-2 is soluble in the organic solvent ethanol. It is also soluble in water. The solubility of TAPI-2 in ethanol and water is approximately 5 and 8 mg/ml, respectively. We do not recommend storing the aqueous solution for more than one day.

Description

The extracellular domains of many different types of transmembrane proteins, including growth factors, growth factor receptors and cell adhesion molecules, are proteolytically released (shed) in response to environmental cues. TNF protease inhibitor 2 (TAPI-2) is a broad-spectrum inhibitor of TNF- α converting enzyme (TACE), other ADAMs (a disintegrin and metalloproteinases), and other matrix metalloproteinases. It inhibits phorbol-12-myristate-13-acetate-induced (PMA) shedding of various cell surface proteins, such as TGF- α , β amyloid precursor protein, L-selectin, and IL-6 receptor α subunit, with an IC₅₀ value of 10 μ M.¹ TAPI-2 inhibits ADAM8, 10, 12, and TACE with K_i values of 10, 3, 100, and 0.12 μ M, respectively.² In T4-2 breast cancer cells, 20 μ M TAPI-2 prevented mobilization of the growth factors TGF- α and amphiregulin leading to reversion of the malignant cellular phenotype.³

Reference

- 1. Arribas, J., Coodly, L., Vollmer, P., et al. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J. Biol. Chem. 271(19), 11376-11386 (1996).
- 2. Moss, M.L. and Rasmussen, F.H. Fluorescent substrates for the proteinases ADAM17, ADAM10, ADAM8, and ADAM12 useful for high-throughput inhibitor screening. Anal. Biochem. 366(2), 144-148 (2007).
- 3. Kenny, P.A. and Bissell, M.J. Targeting TACE-dependent EGFR ligand shedding in breast cancer. J. Clin. Invest. 117(2), 337-345 (2007).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/01/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM